Conversion of glucose into glycogen is a major pathway that contributes to the removal of glucose from the portal vein by the liver in the postprandial state. It is regulated in part by the increase in blood-glucose concentration in the portal vein, which activates glucokinase, the first enzyme in the pathway, causing an increase in the concentration of glucose 6-P (glucose 6-phosphate), which modulates the phosphorylation state of downstream enzymes by acting synergistically with other allosteric effectors. Glucokinase is regulated by a hierarchy of transcriptional and posttranscriptional mechanisms that are only partially understood. In the fasted state, glucokinase is in part sequestered in the nucleus in an inactive state, complexed to a specific regulatory protein, GKRP (glucokinase regulatory protein). This reserve pool is rapidly mobilized to the cytoplasm in the postprandial state in response to an elevated concentration of glucose. The translocation of glucokinase between the nucleus and cytoplasm is modulated by various metabolic and hormonal conditions. The elevated glucose 6-P concentration, consequent to glucokinase activation, has a synergistic effect with glucose in promoting dephosphorylation (inactivation) of glycogen phosphorylase and inducing dephosphorylation (activation) of glycogen synthase. The latter involves both a direct ligand-induced conformational change and depletion of the phosphorylated form of glycogen phosphorylase, which is a potent allosteric inhibitor of glycogen synthase phosphatase activity associated with the glycogen-targeting protein, GL [hepatic glycogen-targeting subunit of PP-1 (protein phosphatase-1) encoded by PPP1R3B]. Defects in both the activation of glucokinase and in the dephosphorylation of glycogen phosphorylase are potential contributing factors to the dysregulation of hepatic glucose metabolism in Type 2 diabetes.
INTRODUCTION
A prime function of the liver is the maintenance of blood-glucose homeostasis by rapid clearance of the glucose that reaches the liver via the portal vein after a meal (postprandial state) and by the controlled production of glucose in the postabsorptive state when an exogenous source of glucose is no longer available. Unlike in extrahepatic tissues, where glucose metabolism is determined by metabolic demand and regulated by end-product inhibition, in the liver, glucose metabolism is determined largely by the glucose concentration in the portal vein (substrate supply) and is regulated by feed-forward activation mechanisms. Accordingly, the liver enzymes that have a major role in the control of glucose metabolism have different kinetic and allosteric properties from the corresponding isoenzymes that are expressed ubiquitously.
The conversion of glucose into glycogen, a branched polymer of glucosyl units, is one of the key pathways by which the liver removes glucose from the portal vein after a meal. Liver glycogen serves as a store of glucosyl residues that can be rapidly reconverted into glucose to maintain blood-glucose homeostasis. The transition from net degradation of glycogen in the fasting state to net synthesis in the postprandial state is regulated primarily by the blood-glucose concentration, as well as by the insulin/glucagon ratio and by a mechanism described as the 'portal signal' that involves autonomic innervation of the liver and is activated by the glucose concentration in the portal vein [1] .
Several enzymes and regulatory proteins are involved in the regulation of hepatic glycogen synthesis from glucose, through either catalysis of the intermediate reactions or through regulation of these enzymes by covalent modification, allosteric inhibition or subcellular targeting [2] . Transport of glucose into the liver cell is mediated by the bidirectional GLUT2 transporter, which is present in the membrane with high activity levels and maintains the intracellular glucose concentration in near-equilibrium with the extracellular concentration. The first reaction of glucose metabolism is the ATP-dependent phosphorylation to glucose 6-P (glucose 6-phosphate), catalysed by glucokinase [3] . Glucose 6-P is converted into glucose 1-P (glucose 1-phosphate) by phosphoglucomutase, and then to UDP-glucose by UDP-glucose pyrophosphorylase. Glycogen synthase catalyses the transfer of glucosyl units from UDP-glucose to glycogen by synthesis of α-1,4 bonds, whereas the branching enzyme transfers a chain of six to eight glucosyl units to a C 6 of a neighbouring chain to form an α-1,6 branch. Glucokinase is regulated by hormonal control of gene transcription [4, 5] and by rapid mechanisms that involve glucose-induced dissociation from a specific glucokinase-binding protein, GKRP (glucokinase regulatory Abbreviations used: AICAR, 5-amino-4-imidazolecarboxamide 1-β-D-ribofuranoside; AMPK, AMP-activated protein kinase; fructose 1-P, fructose 1-phosphate; fructose 2,6-P 2 , fructose 2,6-bisphosphate; GKA, glucokinase activator; GKAP, glucokinase-associated protein; GKRP, glucokinase regulatory protein; glucose 1-P, glucose 1-phosphate; glucose 6-P, glucose 6-phosphate; GP, glycogen phosphorylase; GPa, phosphorylated form of GP; GPb, dephosphorylated form of GP; GSa, active glycogen synthase; GSK3, glycogen synthase kinase 3; HEK-293T cell, human embryonic kidney cell expressing the large T-antigen of simian virus 40; MODY-2, maturity-onset diabetes of the young, Type 2; NES, nuclear export signal; NLS, nuclear localization signal; PHHI, persistent hyperinsulinaemic hypoglycaemia of infancy; PFK-2/FBPase-2, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase; PP-1, protein phosphatase-1; GL, hepatic glycogen-targeting subunit of PP-1 encoded by PPP1R3B; PKA, cAMP-dependent protein kinase; PTG, protein-targeting-toglycogen encoded by PPP1R3C; R-conformation, relaxed conformation; T-conformation, tense conformation.
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Figure 1 Conversion of glucose into glycogen in liver
Glucose (Glc) causes dissociation of glucokinase (GK) from its inhibitory protein GKRP (1) , resulting in activation of glucose phosphorylation, with a consequent increase in glucose 6-P (G6P) concentration (2) . Both glucose and glucose 6-P bind to GP and make it a better substrate for dephosphorylation by PP-1, resulting in increased conversion of the active phosphorylated form, GPa, into the inactive unphosphorylated form (GPb) (3) . GPa is a potent allosteric inhibitor of glycogen synthase phosphatase (GSP) (4) , which catalyses the dephosphorylation (activation) of glycogen synthase. Depletion of GPa releases the inhibition enabling conversion of inactive GSb (inactive glycogen synthase) into active GSa. Glucose 6-P also activates glycogen synthase (conversion of GSb into GSa) by making the enzyme a better substrate for dephosphorylation by glycogen synthase phosphatase (5) . PhK, phosphorylase kinase; PK, protein kinase; UDPG, UDP-glucose.
protein), that acts as a competitive inhibitor as well as a nuclear-binding protein for glucokinase [6] . Glycogen synthase is regulated by multi-site phosphorylation which causes inactivation. Dephosphorylation (activation) is catalysed by glycogen synthase phosphatase [7] , which comprises PP-1 (protein phosphatase-1) in association with glycogen-targeting proteins [8] . Glucose 6-P, the first intermediate in glucose metabolism, activates glycogen synthase both by allosteric stimulation of the inactive phosphorylated form and by enhancing its dephosphorylation by inducing a conformation that is a better substrate for dephosphorylation [7] . GP (glycogen phosphorylase) catalyses the degradation of glycogen by phosphorolysis of the α-1,4 bonds to form glucose 1-P. It is regulated by phosphorylation of a single residue at the N-terminus, catalysed by phosphorylase kinase. The phosphorylated form of GP, designated GPa (phosphorylated form of GP), is the active form responsible for catalysing the degradation of glycogen and is also an allosteric inhibitor of glycogen synthase phosphatase. The phosphorylation state of GP thereby regulates both the degradation and the synthesis of glycogen [2] . The conversion of GPa into GPb (dephosphorylated form of GP) is catalysed by PP-1 and regulated by glucose and glucose 6-P, which make GPa a better substrate for dephosphorylation [9] (Figure 1 ). Control of flux through metabolic pathways is generally not confined to a single regulatory enzyme, but is shared unequally among the pathway enzymes [10] . Two enzymes that exert a very high degree of control over hepatic glycogen metabolism are glucokinase [11] and GP [12] . Changes in glucokinase activity through regulated protein expression or dissociation from GKRP, and of GPa concentration through dephosphorylation of GPa or phosphorylation of GPb, result in large changes in flux through glycogen synthesis. The purpose of this review is to discuss our current understanding of the control of liver glycogen metabolism and the crucial role of glucokinase in this control.
GLUCOKINASE: TISSUE SPECIFIC EXPRESSION
Hexokinase IV (or D), commonly known as glucokinase, is the predominant hexokinase (EC 2.7.1.1) expressed in the liver (in parenchymal hepatocytes) of most mammals, including humans [3] . Hexokinase isoenzymes I, II and III (A, B and C) are expressed at very low levels in rat hepatocytes and account for only a small fraction of glucose-phosphorylating activity under normal physiological conditions [13] . However, they are an important back-up mechanism when glucokinase activity is compromised, as in liver cirrhosis [14] or murine models with liver-specific glucokinase knock-down [15] .
Glucokinase is also expressed in other tissues involved in the control of blood glucose, including pancreatic β-cells, where it functions as the glucose sensor for insulin secretion, and in glucose-sensory cells in the hypothalamus and gut [16] . The glucokinase gene contains two widely separated promoters. The downstream one is active only in hepatocytes and the upstream promoter is active only in extrahepatic glucose sensory-cells. The isoforms differ in the first 12-14 amino acids, but have similar kinetics [4, 15] . Whether the N-terminal difference has a role in subcellular targeting has not been unequivocally excluded. Alternative promoters enable differential regulation of gene transcription in liver and extrahepatic sites. In pancreatic β-cells, glucokinase expression at the mRNA level is largely constitutive, whereas in the liver it undergoes large adaptive changes in response to nutritional states, enabling larger changes in glucokinase activity than would otherwise be possible by post-transcriptional regulation alone [17] .
The major role of glucokinase in the control of blood glucose and hepatic glycogen synthesis is evident from the impaired glycogen synthesis in murine models of liver-specific knockdown of glucokinase [15] and from the effect of glucokinase mutations on glucose homeostasis in human and animal models [16, 18] . In humans, loss-of-function mutations on a single allele result in a form of diabetes known as MODY-2 (maturityonset diabetes of the young, Type 2), characterized by a moderate rise in fasting blood glucose, whereas mutations on two alleles cause a severe form of diabetes known as permanent neonatal diabetes, requiring insulin treatment for survival. Gainof-function mutations on a single allele have been identified in subjects with low blood glucose and raised insulin levels [PHHI (persistent hyperinsulinaemic hypoglycaemia of infancy)]. Murine models of MODY-2 and PHHI show very similar phenotypes to the human diseases, supporting the validity of rodent studies, both in vivo and in vitro, for understanding the role of glucokinase in control of hepatic glycogen metabolism.
GLUCOKINASE: KINETIC ACTIVITY
Like other members of the hexokinase family, glucokinase catalyses the ATP-dependent phosphorylation of glucose and other hexoses [3] .
Glucokinase shares a high degree of sequence similarity with other 50 kDa hexokinases, such as the yeast enzymes and with the other vertebrate hexokinases (I, II and III), which are 100 kDa proteins and are thought to have evolved by duplication and fusion of an ancestral 50 kDa hexokinase [3] . However, it has various unique kinetic properties [3] . These are: its low affinity for glucose and the sigmoidal (rather than hyperbolic) kinetics with respect to glucose (S 0.5 ∼ 7.5 mM), which together confer a high response of glucose-phosphorylating activity to physiological changes in glucose concentration in the portal vein; the slow conformational change on glucose binding, which accounts for the lag-phase in the kinetic assay; and the lack of inhibition by physiological concentrations of its product, glucose 6-P. The latter is an essential property for feed-forward activation of metabolic flux. Another important property is the regulation of glucokinase activity by a 68 kDa regulator protein (GKRP) that functions as a competitive inhibitor of glucokinase [6] . This protein confers an additional level of regulation that enables adaptive changes in the affinity of glucokinase for glucose in hepatocytes. The sigmoidal kinetics of glucokinase with positive cooperativity (Hill coefficient of 1.5-1.8) was discovered 30 years ago [19] . Sigmoidal kinetics can occur commonly if there are multiple subunits or active sites, but is a rare property of monomeric enzymes with a single substrate-binding site and, in such cases, is explained by kinetic models. Two proposed models were the mnemonic model [20] and a ligand-induced slow-transition model [21] . Both assume the existence of two conformational states of the enzyme, with different affinities for glucose, that interconvert slowly on glucose binding. Because the rate of the conformational transition is slow compared with the catalytic cycle, the two conformational states do not reach equilibrium, and the glucose-induced change in distribution between the low-affinity and high-affinity states accounts for the positive co-operativity. The mnemonic model assumes that only the free enzyme has two conformational states and that there is one catalytic cycle [20] , whereas the ligand-induced slowtransition model assumes that the enzyme-glucose complex also exists in two conformations and these undergo catalytic cycles with different kinetics, with the overall rate being the sum of these cycles [21] .
Prior to the crystallization of glucokinase, the glucose-induced interconversion between two glucokinase conformations was supported primarily by two sets of evidence: (i) the lag-phase in the kinetic assay when glucokinase had been stored at (or pre-exposed to) a lower glucose concentration than in the assay [22] ; and (ii) glucose-induced changes in intrinsic tryptophan fluorescence [23] . The assay lag phase had been noted previously [24, 25] . Neet et al. [22] showed that there is a transition between the initial rate and the steady-state rate that is not due to assay artefacts but depends on whether the glucose concentration to which glucokinase is exposed prior to assay is lower (initial lag-phase) or higher (transient burst) than in the assay. The lag phase (∼ 10 min) was interpreted as a glucose-mediated transition. Changes in intrinsic tryptophan fluorescence after the addition or removal of glucose [23, 26] were also consistent with a slow glucose-induced conformational change. The early studies showed an apparent hyperbolic relationship between glucose concentration and the change in protein fluorescence in equilibrium-binding conditions [23] . Recent studies analysed the kinetics of glucose binding using stopped-flow spectrophotometry and demonstrated a biphasic response [26, 27] . The first phase showed a linear dependence on the concentration of glucose and was interpreted primarily as a bimolecular binding event with little conformational change, whereas the second phase showed a clear hyperbolic relation to glucose (K d 3-5 nM) and a large conformational change.
The biphasic kinetics is explained by a reversible 2-step mechanism ( Figure 2 ): a thermodynamically stable free enzyme (E 1 ) binds glucose with low-affinity (k 1 ) to form a transient intermediate with loosely bound glucose. This is followed by a slow conformational change (k 2 ) to a catalytically competent enzyme (E 2 )-glucose complex. ATP is then able to bind to the E 2 -glucose complex and enable a catalytic cycle. After product release, the enzyme is initially in the active E 2 form, which can either relax back (k relaxation ) to the thermodynamically favoured low-affinity E 1 or bind glucose (k 3 ) to re-enter the catalytic cycle [26] (Figure 2 ). The conformational change (E 1 to E 2 ) is estimated In the absence of glucose, glucokinase exists in a thermodynamically stable conformation (E 1 ) with a low affinity for glucose. Binding of glucose (Glc) initiates a biphasic mechanism. The first phase, k 1 , involves reversible formation of a transient intermediate (E 1 -Glc). This is followed by a slow conformational change, k 2 , to a catalytically active form E 2 -Glc, which binds ATP and goes through a catalytic cycle. After product release, the enzyme is in the active high-affinity form E 2 , which can either bind glucose (k 3 ) or relax (k relaxation ) to E 1 . The conformational change (k 2 ) is slow relative to catalytic turnover. The model is based on transient kinetics [26] . G6P, glucose 6-P.
to be approx. 85 times slower than the catalytic cycle at saturating glucose concentration [26] . High-and low-glucose concentrations favour the high-affinity (E 2 ) and low-affinity (E 1 ) conformations respectively. The glucose-induced change in fluorescence for yeast hexokinases that do not show sigmoidal kinetics is orders of magnitude more rapid than for glucokinase [26] . Activating mutations of glucokinase identified in PHHI retain the two-step mechanism. However, some mutations affect the kinetics of the first step (T65I, Y215A and A456V), whereas others accelerate the conformational change (W99R, V455M and Y214A) [28] .
GLUCOKINASE: STRUCTURE
Glucokinase is a 465 amino-acid residue protein [29] . It is highly conserved, with 98 % identity between human and rat. It shares ∼ 50 % identity with the N-terminal and C-terminal halves of hexokinase I (100 kDa), and 28 % identity with yeast hexokinase A [4] .
Hexokinases comprise a bipartite structure of a large domain and small domain that are linked by a flexible hinge and surround the catalytic cleft. The catalytic cycle for hexokinases involves a transition from an 'open' conformation, which binds glucose at the centre of the cleft, to a 'closed' conformation, which binds ATP or glucose 6-P [30] . Glucokinase proved more difficult to crystallize than the yeast hexokinases or the other vertebrate hexokinases because of the greater molecular movement which prevents formation of crystals. Initial structural predictions for glucokinase were based on modelling of yeast hexokinase or brain hexokinase I [31] . Because activating mutations of glucokinase cluster in the hinge, it was predicted that, in addition to the open and closed conformations, analogous to those of other hexokinases, glucokinase exists in other conformations [32] .
Kamata et al. [33] succeeded in crystallizing glucokinase in two conformations by deletion of the N-terminal 11-15 residues and with the help of a pharmacological GKA (glucokinase activator) that binds near the hinge and restricts its opening (Figure 3 ). This was a major breakthrough in understanding glucokinase structure. In the presence of glucose and the GKA, glucokinase lacking the first 11 residues was crystallized in a closed conformation that is analogous to the closed conformation of hexokinase I. In the absence of glucose and the GKA, glucokinase lacking the first 15 residues was crystallized in a wide-open ('super-open') conformation. The unique feature of glucokinase is that the hinge allows much larger movements than in hexokinase I. In the closed conformation, the large and small domains are folded into a palmlike structure similar to that of yeast hexokinases or vertebrate hexokinase I, and the glucose-binding site includes residues in the large domain (Glu 256 and Glu 290 ), the small domain (Thr 168 and Lys 169 ) and the interconnecting region (Asn 204 and Asp 205 ). In the wide-open conformation, the structure of the large domain was unchanged, whereas the small domain was shifted by about 100
• relative to the closed conformation by movement of the C-terminal α-helix from the small domain (closed) to the interdomain region. The displacement of the glucose-binding residues in the wideopen conformation accounts for the low affinity for glucose. In hexokinase I, the interconnecting region between the domains is more rigid and restricts the movement of the C-terminal α-helix [33] .
The current model based on the two crystal structures [33] and the biphasic kinetics [26] is that glucokinase exists in the thermodynamically stable wide-open state in the absence of glucose. After glucose binding, it undergoes a conformational change to the predicted open conformation (E 2 ) and then to the closed conformation, which binds ATP. On completion of the catalytic cycle, it partially opens to release glucose 6-P and ADP. Glucose 6-P is thought to be released first, based on kinetic studies using 2-deoxyglucose [34] . Immediately after product release, the enzyme is in the active conformation, which can relax [33, 35] .
REGULATION OF GLUCOKINASE ACTIVITY BY COVALENT MODIFICATION
Whether covalent modification of glucokinase by phosphorylation of serine/threonine residues and oxidation or nitrosylation of cysteine residues has a physiological role in regulation of hepatic glucokinase activity is not known.
Phosphorylation of purified rat liver glucokinase on a serine residue by PKA (cAMP-dependent protein kinase) with concomitant partial inactivation was reported 20 years ago [36] . More recent work confirmed the phosphorylation and inactivation (∼ 30 %) of recombinant glucokinase by PKA [37] . Glucokinase has a conserved RRXT motif (amino acid residues 428-431) and two RXS motifs (amino acid residues 359-361 and 395-398). The RXS motif is generally a substrate for PKA in vitro but not in vivo, whereas the RRXS/T motif is often a substrate in vivo [38] . Whether phosphorylation of glucokinase by PKA contributes to the inhibition of glucose phosphorylation by glucagon remains to be demonstrated.
Yeast and mammalian hexokinases undergo autophosphorylation of a conserved serine residue (Ser 158 in yeast, corresponding to Ser 151 in glucokinase) [39] [40] [41] with consequent inactivation, because the residue determines affinity for glucose and conformational changes. Autophosphorylation occurs in the conformation that positions the serine residue close to the binding site of the 6-hydroxyl group of glucose [40] . In yeast, autophosphorylation of Ser 158 is stimulated by prior phosphorylation of Ser 14 (a PKA-like motif), which occurs in vivo during glucose deprivation [42] . Human glucokinase also undergoes autophosphorylation in vitro [41] , but whether this has a role in vivo and/or requires prior phosphorylation of other residues is not known.
Glucokinase differs from the other vertebrate and yeast hexokinases in its high cysteine residue content (twelve in glucokinase compared with four in yeast, and eleven in 100 kDa hexokinase I) and in its high sensitivity to sulfhydryl group oxidation [43] . The redox state of the sufhydryl residues affects both catalytic activity and conformation. Glucokinase undergoes a slow decay in activity in the absence of thiol-protective agents [44] . In the absence of glucose, the decay involves a decrease in affinity for glucose and in co-operativity, whereas in the presence of glucose, the decay involves mainly a decrease in V max . The cysteine residues differ in their susceptibility to oxidation or nitrosylation. Four of the residues are within nitrosylation motifs (amino acid residues 220, 364, 371 and 434) and two (amino acid residues 364 and 371) were shown to be nitrosylated in pancreatic β-cells [45] . Whether nitrosylation causes catalytic inactivation was not determined. The interaction of glucokinase with binding proteins may protect glucokinase from inactivation [43, 46] .
PHARMACOLOGICAL GKAs
The recognition that glucokinase plays a major role in the control of blood glucose [47] led to drug discovery programmes in order to identify small molecules which target glucokinase as potential blood-glucose-lowering drugs for Type 2 diabetes [48] . The initial objective was to identify compounds that activate glucokinase indirectly by preventing its binding to GKRP [49, 50] . However, compounds were identified that activate glucokinase directly by binding within a cavity near the hinge in the closed conformation [33] . The cavity involves a ceiling formed by amino acid residues 65-68, and a floor containing hydrophobic residues Figure 2 ). A variety of GKAs have been identified that greatly decrease the S 0.5 for glucose by binding at the allosteric site. Some GKAs have no effect on either co-operativity for glucose or V max [51] , others increase V max without affecting the co-operativity [50] , and others also abolish co-operativity [35] . Similar differential effects on kinetics occur among activating mutations that cluster in the hinge region [28] .
PHYSIOLOGICAL ALLOSTERIC ACTIVATORS OF GLUCOKINASE?
The possible existence of physiological activators of glucokinase was first proposed by Wals and Katz [52] , based on apparent discrepancies between expected and measured rates of glucose phosphorylation determined from labelling of glucose with 2 H 2 O in hepatocytes. The discovery of pharmacological GKAs also raised the question of possible physiological activators [16] . Various proteins have been proposed as candidate activators. Unlike in the case of the inhibitory protein, GKRP [6] (see below), the mechanism by which the putative activators affect glucokinase kinetics has not been rigorously evaluated. Some of these candidates will be discussed below.
A dual-specificity protein phosphatase described as GKAP (glucokinase-associated protein; encoded by DUSP12) was identified as a glucokinase-binding protein from a yeast 2-hybrid screen of a liver cDNA library [37] . It belongs to a family of protein phosphatases that can dephosphorylate phosphotyrosine and phosphoserine/threonine residues. It showed partial dephosphorylating activity towards glucokinase when this was first phosphorylated by PKA. GKAP stimulated glucokinase activity by 30-40 % when present at a 3-5-fold molar excess and 2.5-fold at a 50-fold molar excess, independently of the phosphorylation state of glucokinase. The possible physiological role of this ubiquitous protein as a glucokinase regulator remains to be determined.
The precursor of propionyl-CoA carboxylase β subunit was identified as a glucokinase-binding protein from a yeast 2-hybrid screen of a pancreatic β-cell line cDNA library [53] . It activated glucokinase when present at a 50-100-fold molar excess. Such high concentrations of this precursor protein are unlikely in physiological conditions. Since glucokinase is associated with liver mitochondria [54, 55] , a possible role for a precursor of a mitochondrial protein in targeting glucokinase to mitochondria cannot be excluded.
Baltrusch et al. [56] identified the bifunctional kinase/bisphosphatase PFK-2/FBPase-2 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) as a binding protein for glucokinase from a peptide phage screen and were proposed to have a role as an activator of glucokinase [57] . PFK-2/FBPase-2 catalyses the formation and degradation of fructose 2,6-P 2 (fructose 2,6-bisphosphate). It is a homodimer and the glucokinase-binding site (SLKVWT) is on the bisphosphatase domains located on opposite sides of the dimer. Because activation of glucokinase occurred after prolonged incubation with PFK-2/FBPase-2 [57] in the absence of thiol-protective agents it is not clear whether it results from protection of glucokinase from inactivation as opposed to a rapid and reversible activation mechanism. The liver isoform of PFK-2/FBPase-2 (PFKFB1) is regulated by PKA-and AMPK (AMPactivated protein kinase) mediated phosphorylation of Ser 32 [58] [59] [60] . Whether phosphorylation affects its affinity for glucokinase has not been determined.
Polyubiquitin, a polymer of ubiquitin, and to a lesser extent, ubiquitin itself, a 76-amino-acid protein that is conjugated to lysine residues of proteins and targets these proteins for proteasomal degradation, causes a modest activation of glucokinase [61] . Given the ubiquitous nature of these peptides and their role in triggering protein degradation, it seems rather unlikely that this mechanism could have a positive role in stimulating hepatic glucose phosphorylation.
ALLOSTERIC INHIBITION BY LONG-CHAIN ACYL-CoAs
Long-chain acyl-CoAs are potent allosteric inhibitors of glucokinase, with inhibition constants of approx. 1-2 μM [62] . The inhibition is competitive with respect to both glucose and ATP. Although long-chain acyl-CoAs do not bind to the catalytic site, as shown by the additive inhibition with N-acetylglucosamine, they cause a biphasic increase in intrinsic tryptophan fluorescence similar to that caused by glucose, suggesting the occurrence of a binding event followed by a conformational change [27] . A small inhibitory effect of palmitate on glucose phosphorylation in hepatocytes and a lowering of cellular glucose 6-P has been reported [63] . Accordingly, the physiological suppression of glucokinase activity at elevated concentrations of fatty acids is plausible.
ALLOSTERIC INHIBITION BY GKRP
Undoubtedly, the most exciting breakthrough in our understanding of the regulation of hepatic glucokinase activity was the discovery of the glucokinase inhibitory protein, GKRP, by Van Schaftingen [64] . Two prior observations had suggested the existence of an inhibitory mechanism on glucose phosphorylation in liver. The first was the finding that glucose phosphorylation in intact hepatocytes has a sigmoidal dependence on glucose, but with a lower affinity than expected from the kinetics of the purified glucokinase enzyme (S 0.5 of 20 mM rather than 8 mM). This low affinity was restored to the expected affinity by replacement of extracellular Na + by K + [65] . The second anomalous observation was that micromolar concentrations of fructose stimulates glucose phosphorylation in hepatocytes [66] . Because fructose is metabolized by hepatocytes to fructose 1-P (fructose 1-phosphate), it was postulated that glucokinase is regulated by an inhibitory mechanism that is reversed by fructose 1-P [64] . A protein was identified by fractionation of liver extracts by anion-exchange chromatography that inhibited glucokinase by a mechanism that was reversed by fructose 1-P. This 68 kDa protein, GKRP (626 amino acid residues), forms a dimeric complex with glucokinase and inhibits glucokinase competitively with glucose [64, 67] . Inhibition of glucokinase activity by GKRP in vitro is enhanced by fructose 6-P and counteracted by fructose 1-P, inorganic phosphate or Cl − [68] . The higher affinity for glucose in hepatocytes incubated in a medium with high K + is explained by the higher cytoplasmic Cl − concentration, which dissociates glucokinase from GKRP.
The proposed model is that GKRP exists in two conformations with low-affinity or high-affinity for glucokinase [69] . Fructose 6-P and fructose 1-P, which compete for a common binding site on GKRP [70] , favour the high-affinity and low-affinity states respectively. The interaction of GKRP with glucokinase is conventionally assayed at 25 mM KCl, which corresponds to the cellular Cl − concentration, and in the presence of either fructose 6-P or its analogue sorbitol 6-phosphate [69] . GKRP had not been detected previously because its binding to glucokinase is low in the conventional glucokinase-assay medium containing 100 mM glucose and 100 mM KCl. Binding of glucokinase to GKRP was shown by ultracentrifugation [67] , size-exclusion chromatography [51] , co-immunoprecipitation [71] and yeast 2-hybrid screens [56] . Using a peptide phage-display screen, Baltrusch et al. [56] showed that glucokinase binds to GKRP at a conserved domain (L 181 SAXXVAG 188 ) close to the predicted fructose 6-P/fructose 1-P binding site [70] . The binding domains on glucokinase that interact with GKRP have also been studied using peptide phage-display screens [72] . This identified leucine and asparagine residues that form part of the hinge region and the substrate binding site (Leu 58 /Asn 204 ). Mutation of Leu 58 and Asn 204 abolished enzyme activity and the interaction with GKRP [72] . Inhibition of glucokinase by GKRP is competitive with inhibition by mannoheptulose, but is independent of inhibition by N-acetylglucosamine [68, 73] . Since N-acetylglucosamine and mannoheptulose are thought to stabilize the wideopen and closed conformations respectively, it is inferred that GKRP stabilizes the wide-open state [6] .
GKRP is expressed exclusively in the liver of vertebrates that express glucokinase, including amphibians and reptiles [74] and, during ontogeny, expression of GKRP precedes that of glucokinase. In the rat, GKRP is expressed four days before birth whereas glucokinase is expressed after weaning [74] . Xenopus GKRP shares 57 % identity with rat GKRP, but binds to glucokinase by a mechanism that is independent of fructose 6-P or fructose 1-P [75] , though it is sensitive to Cl − . Human GKRP shares 89 % identity with rat GKRP [76] and differs in that it has a higher affinity for fructose 6-P and is also a more potent glucokinase inhibitor in the absence of fructose 6-P [77] . The latter is probably not meaningful physiologically, because the major regulators of glucokinase binding to GKRP are glucose and fructose 1-P, but not fructose 6-P (see below).
The role of GKRP in regulation of glucose phosphorylation in hepatocytes
The rate of glucose phosphorylation in hepatocytes can be determined from the loss of 3 H from [2-3 H]glucose as 3 H 2 O, which is a function of the rate of glucose phosphorylation and metabolism of glucose 6-P by phosphoglucoisomerase. Fructose and other precursors of fructose 1-P, such as sorbitol and, to a lesser extent, D-glyceraldehyde, stimulate glucose phosphorylation in hepatocytes in parallel with the increase in fructose 1-P, supporting a role for GKRP in inhibiting glucokinase and the reversal of this mechanism by fructose 1-P [78, 79] . Evidence for a correlation between the rate of glucose phosphorylation and the dissociation of glucokinase from GKRP was obtained using a digitonin-release assay that measures the distribution of glucokinase between free and GKRP-bound states in hepatocytes. This assay also helped to identify metabolic conditions that alter glucokinase binding to GKRP in hepatocytes in situ [80] .
The digitonin-release assay involves the sequential incubation of hepatocytes with two types of medium to measure the free and bound glucokinase fractions [11, 80] . The first medium, which releases free glucokinase, contains: digitonin, to permeabilize the plasma membrane; low ionic strength to preserve binding of glucokinase to GKRP [68] ; and Mg 2+ to retain GKRP (and bound glucokinase) within the permeabilized cells [81] . The second medium, which contains KCl (150 mM) to dissociate the glucokinase from GKRP, elutes the bound glucokinase. The validity of this technique is supported by the correlation between free glucokinase and the cell fructose 1-P content in incubations with precursors of fructose 1-P [73] and by the correlation between free glucokinase and the rate of glucose phosphorylation during titrated overexpression of GKRP [82] .
Maximum binding of glucokinase to GKRP in hepatocytes occurs at 5 mM glucose [82] . Dissociation of bound glucokinase is induced by three classes of compounds: (i) precursors of fructose 1-P (such as fructose and sorbitol) and also the ketohexokinase substrate tagatose, which is metabolized to tagatose 1-phosphate, an analogue of fructose 1-P [80, 83] ; (ii) millimolar concentrations of glucose (EC 50 ∼ 20 mM) and the glucose analogues mannoheptulose, 5-thioglucose and glucosamine [84] ; and (iii) pharmacological GKAs [35, 51] . Since GKAs favour the closed conformation of glucokinase [33] , and mannoheptulose and glucosamine mimic the conformational change induced by glucose, the effects of these compounds is explained by a lower affinity of GKRP for the closed conformation. There is strong synergism between precursors of fructose 1-P and glucose analogues on the dissociation of glucokinase [84] [85] [86] . This can be explained by the interaction of these ligands with GKRP or glucokinase respectively. Dissociation of glucokinase from GKRP in hepatocytes by precursors of fructose 1-P occurs more rapidly than dissociation by glucose or mannoheptulose (t 1/ 2 of 2 min compared with >5 min) [80, 83] . The slow effect of glucose analogues can be explained by the slow conformational transition of glucokinase by these ligands [22, 26, 27] . Whether changes in cellular fructose 6-P regulate binding of glucokinase to GKRP remains debatable [87] , because modulation of cellular glucose 6-P (or fructose 6-P) by either inhibition or overexpression of glucose 6-phosphatase has no effect on glucokinase binding [88, 89] .
The glucose-induced dissociation of glucokinase from GKRP is enhanced by insulin [80] and counteracted by glucagon [80] , ethanol and glycerol [83] , resorcinol (an analogue of proglycosyn) [86] , activators of AMPK [60] and ATP depletion [59, 80] . Although the dissociation by precursors of fructose 1-P correlates with cellular fructose 1-P [73] , inhibition by ethanol and glycerol [73, 83] or AMPK activation [60] cannot be explained by changes in fructose 1-P/fructose 6-P, indicating the involvement of other mechanisms, such as covalent modification of GKRP [60] or other binding proteins [90] . GKRP is a substrate for AMPK on Ser 481 (KFQRELSTKWV) [60] within an AMPK motif [XH(X,B)XX(S,T)XXXH], where H is a hydrophobic residue at positions − 5 and + 4 and B is a basic residue [91] . Although activation of AMPK increases the binding of glucokinase to GKRP in hepatocytes, phosphorylation of recombinant GKRP by AMPK counteracts its inhibitory activity on glucokinase [60] , suggesting that GKRP phosphorylation may alter the conformation of the glucokinase-GKRP complex.
The subcellular location of glucokinase and GKRP in hepatocytes
Immunostaining studies have shown that glucokinase is present at a higher concentration in the nucleus than in the cytoplasm if hepatocytes are incubated in medium containing 5 mM glucose [84, [92] [93] [94] [95] [96] [97] [98] and also in the liver of fasted rats [99, 100] . However, infusion of fructose into the portal vein or incubation of hepatocytes with elevated glucose concentrations (>10 mM), precursors of fructose 1-P [92] or GKAs [35, 51] causes net movement of glucokinase from the nucleus to the cytoplasm. Conversely, conditions that promote glucokinase binding to GKRP cause accumulation of glucokinase in the nucleus [59, 60, 92] , suggesting that the bound glucokinase fraction largely represents the nuclear pool. GKRP immunostaining suggests that the protein is present predominantly in the nucleus [92] [93] [94] [95] . The majority of studies [92] [93] [94] [95] [96] , but not all [98, 101, 102] , concluded that GKRP does not move from the nucleus to the cytoplasm during glucose-induced translocation of glucokinase. Despite the close correlation between substrate-induced dissociation of glucokinase from GKRP, determined by the digitonin-release assay and changes in the nuclear/cytoplasmic ratio of glucokinase, two key issues remain unsettled. First, whether there is a cytoplasmic pool of GKRP in addition to the nuclear pool. Secondly, whether glucokinase translocates from the nucleus independently of GKRP or in conjunction with GKRP [98, 101] . Although the widely assumed (but as yet unproven) model is that glucokinase dissociates from GKRP in the nucleus and translocates to the cytoplasm independently of GKRP [92] [93] [94] 103] , this model cannot explain all the available data [98, 101, 104] . It is worth noting that immunostaining indicates the relative concentrations of the protein in the nucleus and cytoplasm, rather than absolute amounts. As the volume of the nucleus is approx. 10 % of the cytoplasmic volume, this method makes it hard to detect the movement of small to moderate amounts of GKRP into the cytoplasm [98] , or indeed to detect cytoplasmic GKRP if less than one-half of the total GKRP is present in the cytoplasm. Thus the presence of a substantial amount of GKRP in the cytoplasm cannot be excluded [98, 101] .
Nuclear import and export of glucokinase
The mechanisms by which glucokinase shuttles in and out of the nucleus are not resolved. Active transport of proteins into and out of the nucleus is dependent on the presence of NLSs (nuclear localization signals) and NESs (nuclear export signals) respectively. However, glucokinase lacks the classical NLS [103] , and may therefore be transported into the nucleus complexed to another protein. This could be GKRP [103, 104] or another glucokinase-binding protein. The exclusive cytoplasmic location of glucokinase in GKRP knock-out mice [93, 105] is unequivocal evidence for the role of GKRP in sequestering glucokinase in the nucleus. It is currently assumed that GKRP has an additional role in mediating the nuclear import of glucokinase, based on dual transfection of glucokinase and GKRP in heterologous cells including Cos-1 [72, 94] , HeLa [94, 103] and HEK-293T cells (human embroyic kidney cells expressing the large T-antigen of simian virus 40) [104] . In HEK-293T and HeLa cells, GKRP and glucokinase accumulate rather uniformly in the cytoplasm and nucleus when these proteins are expressed separately. However, they accumulate in the nucleus when co-expressed [103, 104] . A possible explanation for this is a dual role for GKRP in mediating both nuclear import and retention of glucokinase in the nucleus. It is noteworthy that most experiments cannot discriminate between nuclear retention alone as distinct from an additional role in nuclear import. Shiota et al. [103] proposed a role for GKRP in nuclear import. They showed that glucokinase has a candidate NES, and when expressed in heterologous cells in the absence of GKRP, it does not accumulate in the nucleus in the presence of leptomycin B, an inhibitor of NES-mediated export [103] . It was inferred that glucokinase is not imported into the nucleus in the absence of GKRP. This rests on the assumption that leptomycin B effectively blocks nuclear export of glucokinase. This remains to be demonstrated [98] .
The current prevailing view is that glucokinase is imported into the nucleus as a complex with GKRP [103] . One set of evidence that supports this model is the finding that changes in the nuclear/ cytoplasmic distribution of endogenous GKRP in hepatocytes closely parallels the changes in glucokinase distribution during both substrate stimulation and substrate withdrawal [98, 102] .
The mechanism by which glucokinase is exported from the nucleus is also not established. One commonly held view [94] [95] [96] [97] [98] [99] is that the glucokinase-GKRP complex dissociates in the nucleus and only free glucokinase is exported. A study of potential NES in glucokinase identified a leucine-rich region between amino acid residues 300 and 310 that may mediate the nuclear export of glucokinase after dissociation from GKRP [103] . Constitutive accumulation in the nucleus of full-length glucokinase lacking At 5 mM glucose, glucokinase (GK) is sequestered in the nucleus, bound to GKRP as an inactive complex. In the postprandial state, the elevated glucose concentration causes translocation of glucokinase to the cytoplasm with concomitant translocation of GKRP. The GK-GKRP complex can either dissociate in the nucleus, followed by nuclear export of both glucokinase and GKRP (1), or it may be exported from the nucleus as a complex which then dissociates in the cytoplasm (2) , and the GKRP may either remain in part in the cytoplasm or reshuttle back to the nucleus (3). After absorption of glucose, when the concentration in the portal vein declines to basal levels, glucokinase binds to cytoplasmic GKRP and is imported into the nucleus (4).
the NES remains to be demonstrated. An alternative hypothesis, supported by the observation that GKRP translocates in tandem with glucokinase during substrate stimulation [98, 101] , is that GKRP translocates together with glucokinase either as a dimeric complex or as free proteins. Support for the nuclear export of GKRP not complexed with glucokinase was provided by Bosco et al. [104] . They showed that when GKRP is expressed in HEK-293T cells, it accumulates in the nucleus only in the presence of an inhibitor of NES-mediated export. This supports constitutive shuttling of GKRP out of and into the nucleus in the absence of glucokinase. A model that takes into account the possible mechanisms of nuclear export and import of glucokinase and GKRP based on available results is shown in Figure 4 .
THE ROLE OF CYTOPLASMIC BINDING PROTEINS IN GLUCOKINASE TRANSLOCATION
Most metabolic effectors which inhibit translocation of glucokinase from the nucleus, such as glucagon, ethanol, glycerol, resorcinol and AICAR (5-amino-4-imidazolecarboxamide 1-β-D-ribofuranoside), also lower the cell content of fructose 2,6-P 2 , the substrate and product of PFK-2/FBPase-2 [86, 90] . The liver isoform of PFK-2/FBPase-2 is phosphorylated on Ser 32 by PKA and AMPK [59, 60] , which decreases the kinase/bisphosphatase activity, resulting in depletion of fructose 2,6-P 2 [58, 106] . Glucagon lowers the kinase/bisphosphatase activity by PKA-mediated phosphorylation, whereas ethanol, glycerol and resorcinol have a similar effect, but through a PKA-independent mechanism [86, 107, 108] . The inhibition of translocation by glucagon [90, 92] can be explained by a role for the Ser 32 -dephosphorylated form of PFK-2/FBPase-2 in binding glucokinase in the cytoplasm because expression of a S32A variant counteracts the effect of glucagon [90] . It remains to be determined whether phosphorylation of PFK-2/FBPase-2 on Ser 32 alters its affinity for glucokinase and/or the conformation of the glucokinase-PFK-2/FBPase-2 complex [56] enabling its translocation to the nucleus. The predominant localization of glucokinase in the cytoplasm in hepatocytes of the insulinresistant Zucker (fa/fa) rat, which has increased expression of PFK-2/FBPase-2 and elevated fructose 2,6-P 2 , is consistent with a role for the dephosphorylated PFK-2/FBPase-2 in sequestering glucokinase in the cytoplasm at basal glucose concentration [109] . Defective glucokinase translocation in other models of diabetes that is the result of sequestration of glucokinase in the nucleus rather than the cytoplasm has also been reported [110] [111] [112] . The underlying mechanisms remain to be determined.
The involvement of AMPK activity in the control of glucokinase translocation was shown using low concentrations of AICAR, which activates AMPK without depleting ATP [60] . AMPK phosphorylates both PFK-2/FBPase-2 (Ser 22 and Ser 32 ) [59, 60] and GKRP [60] . Unlike the inhibitory effect of glucagon on glucose-induced translocation [90] , the inhibitory effect of AICAR is only partly reversed by the PFK-2/FBPase-2 S32A variant. This implies a role for either phosphorylation of GKRP or PFK-2/FBPase-2 on Ser 22 in promoting the accumulation of glucokinase in the nucleus [60] .
CONTROL OF GLUCOKINASE AND GKRP EXPRESSION
Transcription of the glucokinase gene in the liver is initiated at the downstream promoter [4] . For reviews of the regulation of promoter activity see [5, 15] . Hepatic glucokinase mRNA levels are very low during fasting and insulin deficiency, but increase markedly during re-feeding or insulin treatment respectively [113, 114] because of induction of the glucokinase gene by insulin and repression by cAMP [115] . Induction by insulin is not potentiated by high glucose concentration [115] , unlike the induction of pyruvate kinase and lipogenic genes [116, 117] . Interestingly, a possible negative role for glucose 6-P in suppressing glucokinase mRNA levels was apparent in rats treated with an inhibitor of glucose 6-P hydrolysis, which caused a marked elevation in hepatic glucose 6-P content and also in the mRNA levels of lipogenic genes. However, it suppressed glucokinase mRNA levels [118] . Whether this is due to elevated glucose 6-P or to secondary endocrine changes remains to be determined. Changes in cellular glucose 6-P may account for the biphasic time course of glucokinase mRNA levels in vivo in the fasted-to-fed transition [113] or after insulin treatment of diabetic rats [114] . Both conditions show a large overshoot of glucokinase mRNA between 1 h and 8 h after the stimulus, which then declines, despite sustained insulin levels [114] . Because the decline coincides with expression of glucokinase, it could be due to elevated glucose 6-P resulting from the increased glucokinase activity [119] .
GKRP mRNA, unlike glucokinase mRNA [115] , is induced by high glucose concentrations [120] , but apparently not by insulin [93] . The up-regulation of GKRP mRNA but not of glucokinase mRNA [115] by glucose can be explained teleologically as adjustment of gene expression in order to restore glucose 6-P homeostasis. Metabolic conditions associated with elevated glucose 6-P such as hyperglycaemia [121, 122] or pharmacological inhibition of glucose 6-phosphatase [118] cause induction of glucose 6-phosphatase, which in turn lowers glucose 6-P. Induction of GKRP mRNA, if associated with parallel changes in protein expression, would lead to suppression of glucose 6-P because of inhibition of glucokinase [82] and thereby represents an analogous response to the induction of glucose 6-phosphatase. Differential regulation of glucokinase and GKRP
Figure 5 GKRP overexpression in hepatocytes decreases glucose phosphorylation
Hepatocytes isolated from fed rats were either untreated (᭺) or treated with an adenoviral vector for overexpression of GKRP by 2-fold relative to endogenous levels (᭹). Glucose phosphorylation was determined at the concentrations of glucose indicated. Results are from [82] and are means + − S.E.M. (n = 3); * P < 0.05, * * P < 0.005 of the effect of GKRP overexpression.
mRNA levels by insulin and glucose respectively predicts that insulin will increase the affinity of the hepatocyte for glucose by increasing the glucokinase/GKRP ratio ( Figure 5 ), whereas high glucose and insulin resistance would have the converse effect (increase in GKRP/glucokinase) and decrease the affinity for glucose, but lower glucose 6-P. The restoration of intracellular glucose 6-P homeostasis is thus achieved at the expense of compromised blood-glucose homeostasis. Glucose-induced aggravation of hyperglycaemia is described as 'glucotoxicity' and is thought to occur during progression of Type 2 diabetes. It was demonstrated experimentally by Brichard et al. [122] . It can be rationalized in terms of prioritizing intracellular glucose 6-P homeostasis over blood-glucose homeostasis. Compromised glucose 6-P homeostasis would otherwise lead to excessive induction of lipogenic genes and development of fatty liver [118] . The importance of metabolite homeostasis, particularly when the metabolite occurs at a pathway branchpoint, was discussed by Kacser and Acerenza [123] . An interesting finding from the studies on GKRP-deficient mice [93, 105] is that GKRP regulates glucokinase protein expression at the post-transcriptional level. GKRP-deficient mice had normal or raised glucokinase mRNA levels, but markedly diminished glucokinase immunoreactive protein. The lowering of glucokinase activity in GKRP −/+ and −/− mice was more marked in the fasted state (38 % and 85 % suppression) than in the fed state (15 % and 52 % suppression), suggesting that, in the fed state, other mechanisms stabilize glucokinase. When fasted GKRP −/− mice were challenged with insulin, they showed a delayed increase in glucokinase mRNA levels, but no increase in glucokinase protein, confirming the importance of GKRP protein in enabling glucokinase protein expression [93] . Since the decline in glucokinase protein during fasting represents mainly protein degradation, the effect of GKRP is most likely due to stabilization of glucokinase from degradation. This was confirmed by simultaneous overexpression of glucokinase and GKRP in hepatocytes using adenoviral vectors [90] . Despite the unequivocal role of GKRP in regulating glucokinase protein levels [93, 105] , the ratio of glucokinase/GKRP undergoes marked changes in different nutritional and endocrine states [74] , suggesting that mechanisms in addition to stabilization by GKRP are involved. The control of glucokinase degradation by GKRP, PFK-2/FBPase-2 and ubiquitination [61] warrants further study.
IS GLUCOKINASE ACTIVITY SUFFICIENT FOR GLYCOGEN SYNTHESIS BY DIRECT AND INDIRECT PATHWAYS?
The question as to whether glucokinase activity is sufficient to account for hepatic glycogen synthesis in the postprandial state arose in the 1980s because rates of glycogen synthesis in isolated hepatocytes incubated with glucose were much lower than expected from in vivo rates. This problem was described as the 'glucose paradox' [124] . It was suggested that either an 'unidentified factor' present in the portal blood facilitates glucose uptake and conversion into glycogen [125] or that glucokinase activity was insufficient to account for conversion of glucose into glycogen [25] . This led to the proposal that hepatic glycogen was synthesized to a significant extent by an 'indirect pathway' from gluconeogenic precursors generated extrahepatically. The question of the unidentified portal factor is still unsettled [1, 126] . The feasibility of an indirect pathway was supported by the stimulation of glycogen synthesis in hepatocytes by gluconeogenic precursors, and by evidence that glucose is incorporated into glycogen in vivo after prior metabolism to threecarbon precursors [25, 124, 127] .
The 'apparent insufficiency' of glucokinase activity was later shown to be due to an underestimation of activity because of the instability of glucokinase activity if KCl and appropriate thiol-protective agents are not used in the assay [24] , or because of interference from other enzymes, such as glucose 6-phosphatase if the microsomal fraction is not removed by 100 000 g sedimentation. Hexokinase III, which is present at high activity in human liver and is inhibited by high glucose concentrations, can also lead to an underestimate of glucokinase activity in the conventional assay [14] . Using optimized assay conditions, the activity of glucokinase in the liver of fed rats is 2-3 and 4-5 μmol/g of liver per min at 10 mM and 100 mM glucose respectively [24] . Estimates for human liver are lower (∼ 1 μmol/g of liver per min at 100 mM glucose) [14, 128, 129] . Rates of glycogen synthesis after a meal or oral glucose load are approx. 1 μmol/g per min in rats and dogs [25, 130, 131] , and somewhat lower in human liver [132] , suggesting that, in the animal models, and probably also in humans (if the underestimation of glucokinase by hexokinase III is taken into account), glucokinase activity is sufficient to account for glycogen synthesis.
Three pathways can be considered for hepatic glycogen synthesis: (i) a direct pathway from glucose (glucose → glucose 6-P → glucose 1-P → UDP-glucose → glycogen); (ii) an intrahepatic indirect pathway whereby glucose is metabolized by glycolysis to 3-carbon precursors, which are then reconverted into glucose 6-P by gluconeogenesis prior to incorporation into glycogen; and (iii) an extrahepatic indirect pathway involving glucose conversion into gluconeogenic precursors in peripheral tissues and hepatic uptake of the precursors and reconversion into glucose 6-P and then into glycogen. Most studies determined the relative contributions of direct as opposed to indirect pathways, but did not discriminate between intrahepatic compared with extrahepatic indirect pathways. Widely varying estimates for the direct pathway contribution have been determined, ranging from 20 % to 90 % (for a critical review, see [127] ). In humans and dogs, the contribution of the direct pathway is approx. 60 % [130] [131] [132] . Moore et al. [130] showed that hepatic glucose uptake could account for both the direct and indirect pathways of hepatic glycogen synthesis, implicating an intrahepatic indirect pathway.
Studies on isolated hepatocytes using dual-labelled glucose also showed that as much as one-half of the glucose incorporated into glycogen recycles via the glycolytic/gluconeogenic pathway by an intracellular (possibly channelled) mechanism [80, 133] . This corroborates the physiological studies [130] that suggest that metabolism of glucose within the liver may be a major component of the 'indirect pathway' of glycogen synthesis as measured in vivo and, accordingly, that glucokinase accounts for hepatic glycogen synthesis by both direct and indirect pathways in the normal physiological state.
EVIDENCE FOR A HIGH CONTROL STRENGTH OF GLUCOKINASE ON GLYCOGEN SYNTHESIS
The key role of glucokinase in the control of hepatic glycogen synthesis is supported by the severely blunted glycogen deposition under hyperglycaemic conditions in MODY-2 [134] , in a mouse model of hepatic glucokinase insufficiency generated using the Cre-Lox-P strategy [135] and by the stimulation of glycogen synthesis by substrate-induced translocation of glucokinase, by pharmacological GKAs or by overexpression of glucokinase in vitro or in vivo.
The stimulation of glycogen synthesis by precursors of fructose 1-P (such as fructose and sorbitol) correlates with glucokinase dissociation from GKRP [80, 82, 83] , suggesting that activation of glucokinase is a likely explanation for the stimulation [80] . However, additional effects of fructose or fructose 1-P on glycogen synthase that are independent of glucokinase activation cannot be unequivocally excluded because fructose 1-P stimulates the inactive form of glycogen synthase [136] and fructose can also activate glycogen synthase through elevated AMP levels [137, 138] . The latter mechanism is unlikely at micromolar concentrations of fructose (<0.2 mM), which do not lower cellular ATP. Studies in vivo showed that infusion of fructose at micromolar concentrations into the portal vein of the dog under hyperglycaemic conditions stimulates hepatic glucose uptake 5-fold, primarily by conversion of glucose into glycogen by the direct pathway [139] . In humans, infusion of fructose during a euglycaemic clamp increased hepatic glycogen synthesis [140] and small amounts of fructose improved glucose clearance during an oral glucose-tolerance test independently of insulin secretion [141] , consistent with a role for glucokinase dissociation from GKRP in the control of liver glycogen synthesis. Pharmacological GKAs that bind to the allosteric site have similar or greater glycogenic effects than precursors of fructose 1-P [35, 51] because of their dual effects on glucokinase dissociation from GKRP and allosteric activation of glucokinase [51] .
Overexpression of glucokinase in hepatocytes with adenoviral vectors has enabled determination of the control strength of glucokinase on glycogen synthesis by titrated enzyme overexpression and application of metabolic control analysis. This analysis describes in quantitative terms how control of flux through metabolic pathways is distributed amongst component enzymes. The 'control strength' or 'flux control coefficient' of an enzyme is defined as the fractional change in flux through the pathway that results from a fractional change in enzyme concentration or activity [142] . It can be determined from the slope of the double log plot of metabolic flux (determined in steady-state conditions) against enzyme concentration [11, 82] . It usually has a value between zero and unity, where values near to zero indicate that the endogenous enzyme concentration is saturating for pathway flux, whereas values approaching unity indicate a strongly limiting enzyme such that an increase in enzyme activity is associated with a nearly corresponding increase in pathway flux. Metabolic control analysis does not provide an explanation for the mechanisms that account for a high or low control strength, but it is a useful quantitative method to understand how control changes in different metabolic conditions. Glucokinase has a very high control strength for a wide range of conditions [11, 82, 143] , but particularly at low glucose concentration. The stimulation of glycogen synthesis by glucokinase overexpression mimics glucose-induced dissociation of glucokinase from GKRP [11] . Thus the function of GKRP is to maintain an inactive reserve of glucokinase in the nucleus which can be mobilized rapidly when the hepatocyte is exposed to an increase in glucose concentration. GKRP has a high negative control strength on glycogen synthesis and overexpression leads to the inhibition of glycogen synthesis [82] . The ratio of glucokinase/GKRP is thus a major determinant of the affinity of the hepatocyte for glucose ( Figure 5) .
Transgenic mice models with a mild elevation of hepatic glucokinase had a decrease (∼ 25 %) in fasting blood glucose, improved glucose tolerance after an oral load [144, 145] and markedly increased (3.5-fold) glycogen synthesis under hyperglycaemic conditions [146] , consistent with the high control strength of glucokinase on glycogen synthesis. Likewise, glucokinase overexpression in liver with adenoviral vectors also improved glucose tolerance and enhanced glycogen synthesis in a mouse model of diabetes induced by a high-fat diet [147] . This corroborates the high control strength of glucokinase on glycogen synthesis determined in vitro [11] .
THE MECHANISM BY WHICH GLUCOSE STIMULATES HEPATIC GLYCOGEN SYNTHESIS
An increase in blood-glucose concentration is a prerequisite for the stimulation of hepatic glycogen synthesis, irrespective of whether the substrate is intrahepatic glucose or gluconeogenic precursors generated extrahepatically [124] . Two mechanisms have been proposed by Stalmans and colleagues [2, 148, 149] and Guinovart and colleagues [7, [150] [151] [152] [153] to explain the activation of glycogen synthase by glucose, leading to the stimulation of glycogen synthesis. Stalmans and colleagues [2] proposed that activation of glycogen synthase by glycogen synthase phosphatase is inhibited by GPa at basal glucose concentrations [148] , and the elevated glucose concentration reverses the inhibition by converting GPa into GPb. Because activation of glycogen synthase commences after GPa has declined below a threshold, the mechanism is described as 'sequential activation' of glycogen synthase [2] . Guinovart and colleagues [7] proposed that the increase in cellular glucose 6-P caused by glucose results in a conformational change in glycogen synthase, making it a better substrate for dephosphorylation (activation) by glycogen synthase phosphatase [150] [151] [152] [153] , and that depletion of GPa is not essential for activation of glycogen synthase by glucose [7] . It was assumed that depletion of GPa in the 'sequential mechanism' is mediated by glucose alone [2] and that activation of glycogen synthase by glucose 6-P is due to a direct effect of this metabolite on glycogen synthase alone [7, 152] . However, more recent data [9, 154] showed that glucose 6-P acts both similarly to glucose [155] and synergistically with glucose in converting GPa into GPb. Accordingly, glucose 6-P has a role in both the 'sequential mechanism' and direct activation of glycogen synthase.
GLUCOSE 6-P CONCENTRATION IS CO-REGULATED BY GLUCOKINASE AND GLUCOSE 6-PHOSPHATASE
In the post-absorptive state, the hepatic glucose 6-P content is approx. 0.1 nmol/mg of protein and it increases 2-fold after a meal [156, 157] . This increase reflects the balance between increased production by glucose phosphorylation and decreased production by suppression of glycogenolysis. The role of the former mechanism can be shown in hepatocytes pre-cultured in 5 mM glucose to deplete endogenous glycogen. In this model, the glucose 6-P content is a sigmoidal function of glucose concentration (S 0.5 of 20 mM) and a linear function of glucokinase activity [9, 89, 119] (Figure 6 ).
Glucose 6-phosphatase catalyses the final reaction in glucose production by glycogenolysis or gluconeogenesis and it also has a major role in buffering the glucose 6-P concentration at elevated glucose, as shown by the marked enhancement of the glucose 6-P content by pharmacological inhibition of glucose 6-phosphatase [89, 118] and the suppression by overexpression of glucose 6-phosphatase [88, 119] . This buffering role is further supported by the induction of glucose 6-phosphatase by hyperglycaemia [121] .
THE HIGH CONTROL STRENGTH OF GLUCOKINASE ON GLYCOGEN SYNTHESIS IS DUE TO GLUCOSE 6-P
The stimulation of glycogen synthesis by glucokinase overexpression [11] or activation [35, 51, 80] can be explained by either increased flux through glucose phosphorylation by substrate supply (glucose → glucose 6-P → glucose 1-P → UDPglucose → glycogen) or by allosteric regulation of GP and glycogen synthase by the elevated glucose 6-P concentration. Support for the latter as opposed to the former mechanism was provided using a pharmacological inhibitor of glucose 6-phosphatase [89] that increases the cellular glucose 6-P content without changing the rate of glucose phosphorylation. Glycogen synthesis, but not glycolysis, correlated with the glucose 6-P content rather than with glucose phosphorylation, and was associated with inactivation of GP and activation of glycogen synthase [89] . This supports a major role for the elevated glucose 6-P concentration in the stimulation of glycogen synthesis.
CO-ORDINATE CONTROL OF GP BY GLUCOSE AND GLUCOSE 6-P
GP is a homodimer of 97.5 kDa monomers bound with high affinity [155, 158] . Its activity is regulated by allosteric effectors and by phosphorylation of a serine residue at the N-terminus by phosphorylase kinase, which converts the enzyme from unphosphorylated GPb into the active phosphorylated GPa. The substrate-saturation curve is sigmoidal and allosteric effectors favour either a relaxed conformation (R-conformation) or a tense conformation (T-conformation) with high or lower affinity for substrate respectively [158] . The T-conformation of GPa is a better substrate for dephosphorylation by PP-1.
There are three isoforms of GP (designated liver, muscle and brain). The liver isoform shares 80 % identity with the other isoforms, but responds differently to allosteric effectors [155] . Glucose is an important physiological regulator of GP in liver [2, 155] . It binds to the catalytic site and stabilizes the inactive T-conformation, resulting in enhanced dephosphorylation (inactivation) [158] . Consequently, GP has been classically regarded as the 'glucose sensor' for control of hepatic glucose production [2] .
AMP and glucose 6-P bind to an allosteric 'nucleotide site' at the subunit interface. The phosphate groups of glucose 6-P and AMP interact with overlapping sites, whereas the glucose and ribose moities occupy different positions such that glucose 6-P and AMP stabilize the T-and R-conformations respectively [159] . Although AMP is a potent activator of muscle GPb, it is only a very weak activator of liver GPb, and liver GPb, unlike muscle GPb, is essentially catalytically inactive in vivo [2] . Glucose 6-P is a potent inhibitor of muscle GPb, but not liver GPb. These different isoform responses to allosteric effectors are not due to differences in affinity for the effector, but to poor coupling between the allosteric and active site in the liver isoform because of a difference at the subunit interface [160] . Glucose 6-P has an inhibitory effect on muscle GPa that is synergistic with glucose [161] , and it enhances dephosphorylation of GPa [162] [163] [164] and inhibits phosphorylation of GPb by phosphorylase kinase [165] .
The effects of glucose 6-P on liver GPa are less well documented. However, studies on hepatocytes support a physiological role for glucose 6-P in converting GPa into GPb by a similar mechanism to glucose [2, 155] . First, an increase in glucose 6-P caused by glucokinase overexpression converts GPa into GPb, whereas suppression of glucose 6-P by overexpression of glucose 6-phosphatase has the converse effect [154] . Secondly, 5-thioglucose, a potent hexokinase inhibitor that prevents the increase in glucose 6-P caused by glucose, partially counteracts the conversion of GPa into GPb by glucose [9] , indicating that the effect of glucose is in part due to glucose 6-P. The concentration of glucose that causes a half-maximal effect in depleting GPa can vary from 23 mM when glucokinase is inhibited with 5-thioglucose to 8 mM when the glucose 6-P concentration is raised by inhibition of glucose 6-phosphatase or overexpression of glucokinase, indicating strong synergism between glucose 6-P and glucose [9, 89] . Glucose 6-P has a half-maximal effect on inactivation of GPa at 0.5 nmol/mg at 5 mM glucose and at lower concentrations at elevated glucose. This supports a physiological role for glucose 6-P in controlling the affinity of GPa for glucose. Thus GP operates as a combined glucose 6-P plus glucose sensor rather than a conventional 'glucose sensor'.
DUAL CONTROL OF GLYCOGEN SYNTHASE BY GLUCOSE 6-P AND BY GPa
Glycogen synthase is a homodimer of 81 kDa monomers. It is regulated by multi-site phosphorylation by various protein kinases including PKA, phosphorylase kinase, AMPK, calmodulindependent kinase, GSK-3 (glycogen synthase kinase 3) and casein kinase-2. Dephosphorylation is catalysed by PP-1 in association with glycogen-targeting proteins [7] . The liver isoform of glycogen synthase shares 70 % identity with the ubiquitous muscle isoform and has seven as opposed to nine phosphorylation sites. Progressive phosphorylation decreases the affinity for the substrate, UDP-glucose, and for the allosteric activator, glucose 6-P [166] . The activation state is conventionally assayed as the activity ratio in the absence/presence of glucose 6-P, representing GSa (active glycogen synthase)/total enzyme [GSa + GSb (inactive glycogen synthase)] because the unphosphorylated form is active in the absence of glucose 6-P, whereas the phosphorylated forms are dependent on allosteric activation by glucose 6-P [166] . Several studies have provided evidence for a correlation between the activity ratio of glycogen synthase and the cellular glucose 6-P content [152] during incubation of hepatocytes with various glucose concentrations and hexokinase inhibitors [150, 164] or during overexpression of glucokinase or glucose 6-phosphatase [119, 167] . This is explained by binding of glucose 6-P to the C-terminus inducing a conformational change that makes the enzyme a better substrate for dephosphorylation [7] . Unlike dephosphorylation of GPa, which has a high affinity for glucose 6-P and reaches saturation at 1-2 nmol/mg (at 5 mM glucose) [89, 154] , dephosphorylation of glycogen synthase in hepatocytes does not appear to reach saturation at high levels of glucose 6-P [119] . The higher affinity of GPa, compared with glycogen synthase, for glucose 6-P is consistent with a dual role of glucose 6-P in depleting GPa over a narrow concentration range of glucose 6-P and in causing independent activation of glycogen synthase at higher glucose 6-P concentrations.
In fed animals, but not in fasted animals, glycogen synthase is largely inactive (phosphorylated) when more than 10 % of GP is present in its phosphorylated state, GPa [2, 168, 169] . This is explained by inhibition of glycogen synthase phosphatase (PP-1 bound to a glycogen-targeting protein) by GPa and can be demonstrated in gel-filtered liver extracts which retain protein phosphatase activity, but not protein kinase activity, because of lack of ATP [148] . After administration of glucose to fed animals, dephosphorylation of GPa proceeds more rapidly than dephosphorylation of glycogen synthase. The latter starts after a lag phase that corresponds to the time required for depletion of GPa below the threshold that inhibits glycogen synthase phosphatase. A lag phase also occurs after glucose addition to perfused liver, isolated hepatocytes and gel-filtered liver extracts [2, 170] . The glycogen synthase phosphatase activity in microsomal or glycogen fractions was inhibited at nanomolar concentrations of GPa (EC 50 ∼ 2-3 nM) [171] . Although trypsin digestion had only small effects on synthase phosphatase activity, it abolished the inhibition by nanomolar concentrations of GPa, confirming an allosteric site for GPa. The GPa-sensitive phosphatase was identified as the glycogen-targeting protein GL (hepatic glycogen-targeting subunit of PP-1 encoded by PPP1R3B; 33 kDa) in association with PP-1 [172] . At least four of the seven [8] glycogen-targeting proteins are expressed in the liver [173, 174] . Immunoprecipitation of these proteins showed that GL accounts for approx. 60 % of total glycogen synthase phosphatase activity in liver extracts, whereas PTG (protein-targeting-to-glycogen encoded by PPP1R3C), PPP1R3D (R6) and PPP1R3E account for the remaining activity [173, 174] . However, whether the latter proteins function predominantly as synthase phosphatases or phosphorylase phosphatases in vivo is uncertain [173, 175, 176] . Of these glycogen-targeting proteins, only GL has an allosteric binding site for GPa [177] . GPa inhibits glycogen synthase phosphatase activity in the dimeric complex of purified PP-1 and GL [GST (glutathione transferase)-GL] with a lower affinity (EC 50 of 100 nM) than in microsomal or glycogen fractions [171, 172] , possibly because glycogen enhances the affinity of GPa for GL [178] . Binding of muscle GPa to recombinant GL was abolished by AMP [172, 177] , as was predicted from earlier work on liver extracts [179] . GPa binds to the C-terminal five residues of GL [177] . Recent crystallography studies showed that the C-terminus of GL binds to GPa at the AMP site [180] , with the terminal carboxylate group of GL (Gly 281 -Pro-Tyr-Tyr 284 ) mimicking the phosphate group of AMP at the dimer interface, the Tyr 284 side chain partially overlapping with the ribose binding site of AMP, and the side chain of Pro 282 binding hydrophobically at the subunit interface. Additional contacts by Tyr 283 account for the tight binding affinity for GL. The crystal structure provided an explanation for the uncoupling by AMP of the inhibition of synthase phosphatase activity by GPa.
ALLOSTERIC ROLE VERSUS CATALYTIC ACTIVITY OF GPa
Drug discovery programmes focusing on GP as a target for Type 2 diabetes identified structurally diverse selective inhibitors of GP [181] that bind to the catalytic site or to allosteric sites and mostly stabilize the T-conformation and convert GPa into GPb [181, 182] . However, some GP inhibitors, for example 1,4-dideoxy-1,4-imino-D-arabinitol that binds at the catalytic site, have the converse effect and stabilize the R-conformation [183, 184] . The availability of these compounds has greatly helped our understanding of the role of GPa as an allosteric effector.
In hepatocyte suspensions [185] and monolayer cultures [12, 186, 187] , indole carboxamides that bind at the subunit interface of the GP homodimer and stabilize the T conformation [182] , cause conversion of GPa into GPb by dephosphorylation and secondary activation of glycogen synthase (irrespective of glucose concentration) by relieving the inhibition of synthase phosphatase (GL-PP-1) by GPa. Although these compounds also dissociate GPa from GL [177, 187] , the activation of glycogen synthase starts after dephosphorylation of GPa [12] , consistent with the sequential mechanism proposed by Stalmans and colleagues [2] . These studies have provided evidence that depletion of GPa (by dephosphorylation) in the absence of elevated glucose 6-P is sufficient to activate glycogen synthase [12] . Interestingly, indole carboxamides also cause dephosphorylation of GPa and activation of glycogen synthase in human muscle-cell cultures, which express GL [188] . In other studies that used GP inhibitors that bind to the catalytic site [168] or the AMP site [169] , there was negligible activation of glycogen synthase by the GP inhibitor, despite depletion of GPa at basal glucose concentrations. However, activation of glycogen synthase occurred at high glucose concentrations which raised glucose 6-P. The interpretation of these studies was that depletion of GPa is a prerequisite for activation of glycogen synthase, but that elevated glucose 6-P is also essential [149] . Because the latter inhibitors have not been compared in the same study as indole carboxamides (which activate glycogen synthase irrespective of glucose concentration), it remains unclear whether differences in experimental models or in inhibitor class account for the greater efficacy on activation of glycogen synthase by indole carboxamides in the former studies [12, 185] .
The argument against a role for GPa in the regulation of glycogen synthase [7] was in part based on incubations with fructose that activates glycogen synthase, despite concomitant conversion of GPb into GPa [7, 137, 138] . The latter is due to depletion of ATP and elevation of AMP, which stabilizes the R-conformation [137, 155] . The activation of glycogen synthase can now be explained by dissociation of GPa from GL by AMP [180] . A recent study reported the identification of a compound that inhibits the interaction of GL with GPa without altering the interconversion of GPa and GPb [187] . The compound caused a similar activation of glycogen synthase as GP inhibitors that bind to either the indole carboxamide site or the AMP site and convert GPa into GPb, confirming that the action of the latter compounds on glycogen synthase activation can be fully explained by reversal of the inhibition of GL-PP-1 by GPa [187] .
It is often assumed that stimulation of glycogen synthesis by a GP inhibitor is indicative of cycling between glycogen synthesis and degradation. Although this conclusion might seem justified if the stimulation of glycogen synthesis is not associated with activation of glycogen synthase [168] , nonetheless there is evidence for a role for GPa in regulating glycogen synthesis by mechanisms other than dephosphorylation of glycogen synthase. In hepatocytes, glycogen synthesis is stimulated by GP inhibitors that stabilize the T-conformation of GP and convert GPa into GPb [12, 89, 185] , but not by potent GP inhibitors that stabilize the R-conformation [184, 189] . The latter is consistent with a lack of cycling between glycogen degradation and synthesis [190] and with a negative allosteric role for GPa in the regulation of glycogen synthesis (through activation of glycogen synthase or other mechanisms). Indole carboxamides that cause depletion of GPa and activation of glycogen synthase, cause greater stimulation of glycogen synthesis than inhibitors of GSK-3, which cause comparable activation of glycogen synthase without depleting GPa [191] . In addition, indole carboxamides and AMP-site inhibitors cause a greater stimulation of glycogen synthesis than compounds that dissociate GPa from GL without dephosphorylating GPa, despite a similar activation of glycogen synthase by the three classes of compounds [187] . This implies a role for GPa in stimulating glycogen synthesis by a mechanism additional to the dephosphorylation of glycogen synthase [191] . One hypothesis is that GPa regulates the location of glycogen synthase by competing for binding to a glycogen-targeting protein [175] . GPa and glycogen synthase bind competitively to PTG [192] . A role for translocation of glycogen synthase (possibly through competitive binding with GPa) in explaining the additional stimulation of glycogen synthesis during depletion of GPa is supported by three sets of results: first, the correlation between glycogen synthesis and translocation of glycogen synthase under various conditions involving depletion of GPa [9, 175, 186, 191] ; secondly, the large stimulation of glycogen synthesis by overexpression of PTG [193, 194] that is associated with the translocation of glycogen synthase to the particulate fraction [175] ; and thirdly, the high stimulation of glycogen synthesis by overexpression of glycogen synthase [195, 196] , but not by activation of the endogenous enzyme [191] , which supports a role for competitive binding of glycogen synthase protein as distinct from its catalytic activity.
Elevated glucose concentrations cause redistribution of glycogen synthase in hepatocytes [7] . In subcellular fractionation studies, this is seen as movement from a soluble to a particulate fraction [197, 198] , whereas immunostaining shows translocation from a diffuse cytoplasmic location to the cell periphery, where it colocalizes with newly synthesized glycogen [199] . The effect of glucose is blocked by hexokinase inhibitors and mimicked by glucokinase overexpression, indicating a role for glucose 6-P or downstream mechanisms [7] . GP translocates in tandem with glycogen synthase from the soluble to the particulate fraction during elevation of glucose 6-P [9] and also during overexpression of PTG or treatment of hepatocytes with a ligand of GP that promotes its dephosphorylation [175] . Although enzyme translocation correlates with newly formed glycogen, it is not secondary to glycogen deposition because translocation is not blocked by inhibition of glycogen synthesis [9] . Whether GP and glycogen synthase translocate as a complex with a glycogen-targeting protein is not known. However, the enhanced A tentative hypothesis is that the elevated GPa concentration and glycogen synthase activity in the fasted state [168] reflect a lack of co-localization of these proteins, rather than constitutive cycling. An elevation in blood-glucose concentration during feeding causes translocation of glucokinase from the nucleus to the cell periphery [95] and dissociation from GKRP, with a consequent rise in glucose 6-P concentration. The latter promotes conversion of GPa into GPb by dephosphorylation and translocation of GP to a particulate fraction [9, 154] . The elevation in glucose 6-P and depletion of GPa enable activation and translocation of glycogen synthase [168] to the site of glycogen synthesis in the cell periphery in a microcompartment containing glucokinase, GL and GPb [197, 198] . Because GPb is catalytically inactive [2] , there is negligible cycling between synthesis and degradation, despite co-localization of GSa and GPb at the site of glycogen synthesis. After complete absorption of dietary glucose when glycogen repletion is complete and the glucose concentration in the portal vein declines, the insulin/glucagon ratio falls, resulting in conversion of GPb into GPa and initiation of glycogenolysis as well as inactivation of glycogen synthase. Activation of glycogenolysis generates glucose 6-P. However, the potent inhibition of the GL-PP-1 complex by GPa overrides the effect of glucose 6-P that would otherwise favour dephosphorylation of glycogen synthase. Thus the inhibition of glycogen synthase phosphatase by GPa [2] is crucial during the postprandial state when GP and glycogen synthase are localized in the same subcellular compartment. Understanding the roles of the four or more [8, 173, 174] glycogen-targeting proteins that are expressed in the liver and the subcellular location and translocation of enzymes involved in hepatic glycogen metabolism remains a major challenge.
PHYSIOLOGICAL IMPLICATIONS AND PERSPECTIVES FOR TYPE 2 DIABETES
The hallmark of Type 2 diabetes is the elevated blood-glucose concentration during fasting, when the liver is the major source of glucose production by glycogenolysis and gluconeogenesis. Whereas glycogenolysis is regulated by rapid changes in the phosphorylation state of GP, gluconeogenesis is regulated by slower mechanisms through changes in gene expression. Glucose regulates hepatic glucose production through either a direct effect on the liver or through secondary endocrine changes [200] . Studies using euglycaemic and hyperglycaemic clamps have provided evidence for a defect in Type 2 diabetes in the rapid suppression of hepatic glucose production by glucose (sometimes described as 'glucose effectiveness') [201, 202] . Since glucose inactivates GPa, and thereby glycogenolysis, through a synergistic mechanism with glucose 6-P [9] , perturbations in the concentration of this metabolite through either down-regulation of glucokinase expression or up-regulation of glucose 6-phosphatase may account for the decline in glucose effectiveness in diabetes.
It can be hypothesized that, in insulin resistance, the elevated blood-glucose in the postprandial state increases the hepatic glucose 6-P content through increased flux through glucokinase ( Figure 7 ). Elevated glucose 6-P in turn up-regulates gene expression of lipogenic enzymes [116] , but also of glucose 6-phosphatase [118] . The latter mechanism serves to restore intracellular glucose 6-P homeostasis [88, 89] . While synergism between glucose and glucose 6-P in the postprandial state enhances glycogen storage, the elevated glucose 6-phosphatase would suppress glucose 6-P during the fasting state, which in turn diminishes the sensitivity of GP to glucose. Elevated glucose Insulin resistance and impaired glucose tolerance is due to both genetic and environmental factors. Prolonged hyperglycaemia in the postprandial state causes sustained elevation of hepatic glucose 6-P, which induces gene expression of both lipogenic enzymes and glucose 6-phosphatase (G6Pase). The former effect leads to elevated de novo lipogenesis [206] , whereas increased expression of glucose 6-phosphatase down-regulates the liver-cell content of glucose 6-P during fasting and thereby attenuates glucose effectiveness in suppressing hepatic glucose production (HGP) because glucose 6-P and glucose inactivate glycogenolysis synergistically [9] .
6-phosphatase in Type 2 diabetes has been reported [128, 203] , whereas glucokinase activity was found to be decreased in morbidly obese subjects with diabetes [204] , but elevated in newly diagnosed subjects with Type 2 diabetes [128] . Hepatic glycogen synthesis, which is expected to parallel glucokinase activity [11] , is decreased in subjects with Type 2 diabetes [205] or glucokinase mutations (MODY-2) [134] , but not in insulin resistance [206] , suggesting that the decline in hepatic glucokinase may be a late event in development of Type 2 diabetes.
Although there is limited data on the hepatic glucose 6-P concentration in human insulin resistance and Type 2 diabetes, de novo lipogenesis may be a good surrogate marker for elevated glucose 6-P in the postprandial state, because lipogenic genes are induced by glucose 6-P [116] . Recent evidence shows that subjects with insulin resistance have markedly elevated de novo hepatic lipogenesis and a mild elevation in fasting blood-glucose despite normal hepatic glycogen synthesis [206] . Thus a rise in postprandial glucose 6-P in insulin resistance may lead to both elevated de novo lipogenesis [206] and elevated glucose 6-phosphatase expression which in turn contributes to the decrease in glucose effectiveness in suppressing hepatic glucose production during fasting. Inhibitors of GP that act synergistically with glucose in promoting inactivation of GPa would be expected to compensate for the decline in glucose effectiveness [201, 202] and improve glycaemic control during fasting [181] . Conversely, activators of glucokinase would be expected to have beneficial effects in conditions of compromised glucokinase activity and glycogen synthesis [35] . It is noteworthy, however, that a lack of pharmacological elevation of glucose 6-P is critical to prevent compensatory induction of glucose 6-phosphatase and lipogenic genes. Targeting multiple intrahepatic sites, as opposed to a single site, minimizes perturbations in intracellular metabolite homeostasis [186] and is less likely to lead to tachyphaxis [48] .
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